Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC008 in Inclusion Body Myositis (IBM)
NCT04659031Phase 1Completed
- Sponsor
- Abcuro
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulviprubart in inclusion body myositis (IBM), sponsored by Abcuro. Primary endpoint: Assessment of Safety and Tolerability at 52 weeks. Started May 2021; status: completed.
02
Drugs
ulviprubart
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT04659031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659031.